Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.42 |
| ▸ | PDE5A | O76074 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208287 | 1.00 | LMNA (0.48) | LMNATP53KCNH2PDE5APOLB | |
| SCHEMBL2205783 | 0.83 | HTR1D (0.45) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2205777 | 0.83 | HTR1D (0.45) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2204321 | 0.83 | LMNA (0.52) | LMNATP53KCNH2PDE5APOLB | |
| SCHEMBL2204313 | 0.83 | LMNA (0.52) | LMNATP53KCNH2PDE5APOLB | |
| SCHEMBL2207689 | 0.78 | KCNH2 (0.46) | LMNATP53KCNH2POLBSLC2A1 | |
| SCHEMBL2207697 | 0.78 | KCNH2 (0.46) | LMNATP53KCNH2POLBSLC2A1 | |
| SCHEMBL2201849 | 0.77 | MEN1 (0.40) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL2201851 | 0.77 | MEN1 (0.40) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL2205336 | 0.73 | LMNA (0.48) | LMNATP53KCNH2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888574-B1 | NEW ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | EP | claimed |
| US-20080280888-A1 | Antibiotics Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-13 | — | — | US | claimed |
| US-7981886-B2 | Antibiotics derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| EP-1888574-B1 | NEW ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080280888-A1 | Antibiotics Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280888-A1 | Antibiotics Derivatives | NR4A1, NR2C2, NR4A3 | LMNA 2688/4885TP53 4300/4885KCNH2 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.